C.R. Bard authorizes another share repurchasing program worth $500 million.
C.R. Bard (NYSE:BCR) said it plans to buy back as much as $500 million worth of its own stock, having spent all but $30 million of a prior share repurchasing plan also worth half a billion.
Companies often buy back their stock when they believe the market is undervaluing share prices, in an effort to raise the price.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1pN1Sbu
Cap comentari:
Publica un comentari a l'entrada